MIM
STLN

MetLife Investment Management’s Starling Oncology STLN Stock Holding History

MetLife Investment Management’s Portfolio STLN Stock Details STLN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$252K Buy
46,402
+18,612
+67% +$78.2K ﹤0.01% 2300
2026
Q1 		$85.3K Sell
27,790
-12,665
-31% -$38.8K ﹤0.01% 2603
2025
Q4 		$144K Buy
40,455
+18,819
+87% +$69.8K ﹤0.01% 2437
2025
Q3 		$75.5K Sell
21,636
-18,309
-46% -$62.7K ﹤0.01% 2746
2025
Q2 		$81.9K Buy
+39,945
New +$99.9K ﹤0.01% 2639

Other funds holding STLN

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
DM
Deerfield Management New York $9.59B AUM 113.36% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
JAIC
Josh Arnold Investment Consultant Edina, Minnesota $159M AUM 142.62% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return
WC
Wexford Capital West Palm Beach, Florida $782M AUM 62.56% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Nuveen
Nuveen Charlotte, North Carolina $419B AUM 43.02% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return

MetLife Investment Management's STLN Position: Q2 2026 in Review

MetLife Investment Management increased its Starling Oncology (STLN) stake by 67% in Q2 2026, buying an estimated $78.2K and bringing the position to 46,402 shares worth $252K. The position accounts for ﹤0.01% of the portfolio, ranked #2300.

MetLife Investment Management first reported a position in STLN in Q2 2025 and has held it in 5 quarters since. 119 funds tracked by Wall St. Rank hold STLN as of Q2 2026.

  • MetLife Investment Management held 46,402 shares of Starling Oncology worth $252K as of Q2 2026.
  • MetLife Investment Management bought 18,612 Starling Oncology shares in Q2 2026, an estimated $78.2K.
  • Starling Oncology made up ﹤0.01% of MetLife Investment Management's portfolio in Q2 2026, its #2300 holding.
  • MetLife Investment Management first reported a position in Starling Oncology in Q2 2025 and has held it in 5 quarters since.
  • 119 funds tracked by Wall St. Rank held Starling Oncology as of Q2 2026.

Based on MetLife Investment Management's 13F filing for Q2 2026, filed 14 Aug 2026.